ASSURE Wearable ECG vs AVIEW

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Kestra Medical Technologies
VS
by Coreline Soft Co.

AI Verdict

Tool A, ASSURE Wearable ECG, is designed for continuous heart rate monitoring and data collection via a wearable device, focusing on remote patient management for cardiac patients. Tool B, AVIEW, is an AI platform that analyzes CT scans for the early detection, diagnosis, and monitoring of conditions such as lung cancer, COPD, and coronary artery calcification, primarily enhancing diagnostic precision in radiology. While both have applications in cardiology, their methodologies (wearable ECG vs. CT imaging analysis) and primary use cases are distinct.

Choose ASSURE Wearable ECG if…

Choose ASSURE Wearable ECG if you need continuous, real-time heart rate monitoring and event detection for at-risk cardiac patients in an ambulatory setting. This tool is ideal for identifying transient cardiac events that might be missed by intermittent monitoring, providing clinicians with immediate alerts and comprehensive physiologic trend data for timely intervention.

View ASSURE Wearable ECG →

Choose AVIEW if…

Choose AVIEW if your practice requires an AI-powered platform to enhance the precision and efficiency of diagnosing and monitoring lung conditions and coronary artery calcification from CT scans. This solution is best suited for radiologists and pulmonologists seeking automated analysis for lung nodules, emphysema, and coronary artery calcium scoring, along with streamlined workflow integration.

View AVIEW →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature ASSURE Wearable ECG AVIEW
Pricing Unknown Subscription; one-off payment
Deployment The ASSURE system is intended for use by a patient during their normal daily activities primarily in the home or community setting, but also hospitals, medical clinics, healthcare facilities and transport. Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW

Tool B, AVIEW, demonstrates superior usability for its target audience by significantly streamlining radiology workflows, with clinical validation showing 89% faster case throughput and a 60% reduction in interpretation time. Its integration with existing PACS/RIS/CIS systems and comprehensive reporting features enhance efficiency for radiologists.

Clinical Value

AVIEW

AVIEW offers comprehensive AI-driven solutions for early detection, diagnosis, and monitoring of multiple thoracic conditions, including lung cancer, COPD, and coronary artery calcification, enhancing diagnostic precision. Its widespread adoption as a standard AI platform in national lung cancer screening programs across Europe and integration into major U.S. medical centers underscores its proven clinical impact and value.

Pricing & Value

AVIEW

Tool B, AVIEW, offers greater transparency in its pricing model, specifying options for subscription or one-off payments based on the number of installations and users. In contrast, Tool A, ASSURE Wearable ECG, only states 'contact for pricing,' providing less clarity for potential buyers.

Enterprise Readiness

AVIEW

AVIEW demonstrates higher enterprise readiness through its flexible deployment options (cloud, hybrid, local, virtualized) and explicit integration capabilities with PACS/RIS/CIS. Its extensive global adoption, having processed over 2.5 million cases across 19 countries and being validated against IHE and FHIR standards, indicates robust scalability and proven integration within diverse healthcare ecosystems.

Innovation

AVIEW

AVIEW's innovation lies in its comprehensive, multi-disease AI platform that integrates various analyses for thoracic CT imaging (lung nodules, COPD, CAC, ILD) into a single, streamlined workflow. This represents a significant 'paradigm shift from task-specific tools to an integrated diagnostic ecosystem' in radiology AI, offering a more holistic approach to diagnosis.

Support & Docs

ASSURE Wearable ECG

Tool A, ASSURE Wearable ECG, explicitly mentions that a 'Kestra patient service representative (PSR) fits and trains the patient on proper use and care of the system,' indicating a structured support mechanism for its end-users. While Tool B is widely adopted, the provided information does not detail its specific support or documentation offerings for clinicians or administrators.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature ASSURE Wearable ECG AVIEW
Name ASSURE Wearable ECG AVIEW
Company Kestra Medical Technologies Coreline Soft Co.
Description A non-therapeutic device for continuous heart rate monitoring and data collection, integrated into their digital healthcare platform for at-risk cardiac patients. AI platform offering comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, enhancing diagnostic precision and streamlining radiology workflows.
Categories Cardiology AI, Wearables & Remote Monitoring (RPM) Cardiology AI, Oncology AI, Radiology & Imaging AI
Specialties Cardiology Cardiology, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring ASSURE Wearable ECG and AVIEW.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The ASSURE Wearable ECG is a non-therapeutic device designed for continuous heart rate monitoring and data collection for at-risk cardiac patients, providing physiologic trend data and automatic episode storage. AVIEW is an AI platform that offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans.
The ASSURE Wearable ECG utilizes a wearable device with non-adhesive, embedded ECG sensors to continuously monitor heart rate, employing the ASSURE Detection Algorithm with Quad Channel Processing and Adaptive Patient Intelligence for motion artifact filtering. AVIEW processes medical images, specifically CT scans, using AI to analyze features such as lung nodules, emphysema, and coronary artery calcification, generating 3D visualizations and comprehensive PDF reports.
The ASSURE Wearable ECG is primarily designed for Cardiology, focusing on continuous remote monitoring of cardiac patients. AVIEW supports Cardiology, Pulmonology, and Radiology, offering AI-driven diagnostic assistance across these specialties.
The ASSURE Wearable ECG provides continuous heart rate monitoring, automatic episode storage, alert-based notifications, and physiologic trend data for clinician review. AVIEW offers coronary artery calcium (CAC) scoring, including Agatston, volume, and mass scores, along with risk stratification, derived from CT scan analysis.

Backers

Who funded each tool's parent company.

ASSURE Wearable ECG

AI Tool Finder
AI-powered search. Results may not be comprehensive.